Companies Dominating the Neurotrophic Keratitis Landscape
- Dompe Farmaceutici SpA
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Oyster Point Pharma, Inc.
- Neuroptica, Inc.
- Recordati Rare Diseases
- KALA BIO
- ReGenTree, LLC
- BRIM Biotechnology, Inc.
- Bausch + Lomb Incorporated
- Oculis
- HLB Therapeutics
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Neurotrophic Keratitis Market in 2025 is evaluated at USD 5.68 billion.
The global market size crossed USD 5.37 billion in 2024 and is likely to register a CAGR of over 7.1%, exceeding USD 13.1 billion revenue by 2037.
North America is estimated to surpass USD 4.19 billion by 2037, attributed to dominance of large players and increasing new product launches.
The major players in the market include Dompe Farmaceutici SpA, Oyster Point Pharma, Inc., Neuroptica, Inc., Recordati Rare Diseases, KALA BIO, ReGenTree, LLC, BRIM Biotechnology, Inc., Bausch + Lomb Incorporated, Oculis, HLB Therapeutics.
